Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CHEKOTCMKTS:NIMUNASDAQ:QNRXOTCMKTS:SIGY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHEKCheck-Cap$0.77+0.6%$0.81$0.56▼$3.04$4.45M0.22378,916 shs14,860 shsNIMUNon-Invasive Monitoring Systems$0.01-24.3%$0.01$0.00▼$0.02$820K1.25,724 shs21,100 shsQNRXQuoin Pharmaceuticals$9.27-4.7%$7.89$5.01▼$54.95$5.72M1.44137,148 shs2,454 shsSIGYSigyn Therapeutics$2.75$3.18$2.49▼$5.75$4.41M-1.18100 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHEKCheck-Cap0.00%+3.59%-7.83%-3.16%-62.68%NIMUNon-Invasive Monitoring Systems0.00%-24.29%-29.33%+60.61%-55.08%QNRXQuoin Pharmaceuticals-4.73%+6.55%-1.07%+9.54%-55.11%SIGYSigyn Therapeutics0.00%0.00%+10.44%-31.25%-47.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHEKCheck-Cap1.264 of 5 stars0.05.00.00.03.30.00.6NIMUNon-Invasive Monitoring SystemsN/AN/AN/AN/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals0.918 of 5 stars0.04.00.00.01.90.01.3SIGYSigyn TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHEKCheck-Cap 0.00N/AN/AN/ANIMUNon-Invasive Monitoring Systems 0.00N/AN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ASIGYSigyn Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHEKCheck-CapN/AN/AN/AN/A$4.05 per shareN/ANIMUNon-Invasive Monitoring SystemsN/AN/AN/AN/A($0.01) per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ASIGYSigyn TherapeuticsN/AN/AN/AN/A($2.78) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHEKCheck-Cap-$17.57M-$3.00N/A∞N/AN/AN/AN/AN/ANIMUNon-Invasive Monitoring Systems-$110KN/A0.00∞N/AN/AN/A-251.43%N/AQNRXQuoin Pharmaceuticals-$8.96M-$48.81N/AN/AN/AN/A-148.97%-77.23%8/14/2025 (Estimated)SIGYSigyn Therapeutics-$3.34M-$4.57N/A∞N/AN/AN/A-2,014.27%N/ALatest NIMU, QNRX, SIGY, and CHEK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025SIGYSigyn TherapeuticsN/A-$0.42N/A-$0.42N/AN/A5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A4/15/2025Q4 2024SIGYSigyn TherapeuticsN/A-$2.51N/A-$2.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHEKCheck-CapN/AN/AN/AN/AN/ANIMUNon-Invasive Monitoring SystemsN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASIGYSigyn TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHEKCheck-CapN/AN/AN/ANIMUNon-Invasive Monitoring SystemsN/A0.030.03QNRXQuoin PharmaceuticalsN/A2.572.57SIGYSigyn TherapeuticsN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHEKCheck-Cap1.07%NIMUNon-Invasive Monitoring Systems0.12%QNRXQuoin Pharmaceuticals8.63%SIGYSigyn Therapeutics10.01%Insider OwnershipCompanyInsider OwnershipCHEKCheck-Cap0.48%NIMUNon-Invasive Monitoring Systems28.80%QNRXQuoin Pharmaceuticals3.70%SIGYSigyn Therapeutics78.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHEKCheck-Cap805.85 million5.82 millionNot OptionableNIMUNon-Invasive Monitoring Systems3154.81 million110.23 millionNot OptionableQNRXQuoin Pharmaceuticals4590,000566,000Not OptionableSIGYSigyn Therapeutics51.61 million346,000Not OptionableNIMU, QNRX, SIGY, and CHEK HeadlinesRecent News About These CompaniesSigyn Therapeutics Delays Q1 2025 10-Q FilingMay 15, 2025 | tipranks.comSigyn Therapeutics Delays Yearly Report FilingMarch 31, 2025 | tipranks.comSigyn CEO Note: An Emerging New Industry, 15 Years in the MakingMarch 12, 2025 | finance.yahoo.comSigyn CEO Note: Combating the Rising Threat of New Pandemic VirusesMarch 5, 2025 | finance.yahoo.comSigyn Therapeutics to be Featured in Fireside Chat With Zacks Healthcare AnalystFebruary 25, 2025 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow’s Small Cap Growth Virtual Investor ConferenceFebruary 5, 2025 | financialpost.comFSigyn Therapeutics to Present at Tomorrow's Small Cap Growth Virtual Investor ConferenceFebruary 5, 2025 | globenewswire.comSigyn Therapeutics Announces the Appointment of Michael Ryan to Its Board of DirectorsJanuary 29, 2025 | finance.yahoo.comSigyn Therapeutics, Inc. (SIGY)December 21, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 76 Day 2 on October 31 Register NowOctober 30, 2024 | markets.businessinsider.comPresenting on the Emerging Growth Conference 74 Day 2 on August 22 Register NowAugust 21, 2024 | finance.yahoo.comOTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand ViewingAugust 2, 2024 | finance.yahoo.comSigyn Therapeutics Reports First Quarter 2024 Financial ResultsMay 15, 2024 | finance.yahoo.comSigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"May 7, 2024 | finance.yahoo.comSigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth ConferenceMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow's Emerging Growth ConferenceMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics™ to Present at Tomorrow's Emerging Growth ConferenceMarch 5, 2024 | globenewswire.comSigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-KFebruary 21, 2024 | globenewswire.comSigyn Therapeutics, Inc.: Sigyn Therapeutics Completes Reverse Stock SplitFebruary 2, 2024 | finanznachrichten.deSigyn Therapeutics Announces 1-for-40 Reverse Stock SplitFebruary 1, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNIMU, QNRX, SIGY, and CHEK Company DescriptionsCheck-Cap NASDAQ:CHEK$0.76 +0.00 (+0.64%) Closing price 06/27/2025 03:49 PM EasternExtended Trading$0.81 +0.05 (+6.14%) As of 06/27/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.Non-Invasive Monitoring Systems OTCMKTS:NIMU$0.0053 0.00 (-24.29%) As of 06/26/2025 02:30 PM EasternNon-Invasive Monitoring Systems, Inc. does not have significant operations. Previously, it was involved in the research, development, manufacture, marketing, and sale of non-invasive, motorized, and whole body periodic acceleration platforms. The company was incorporated in 1980 and is based in Miami, Florida.Quoin Pharmaceuticals NASDAQ:QNRX$9.27 -0.46 (-4.73%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$9.30 +0.03 (+0.32%) As of 06/27/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sigyn Therapeutics OTCMKTS:SIGY$2.75 0.00 (0.00%) As of 06/24/2025Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
